生物试剂
>
生化试剂
>
信号通路
> Conoidin A
加入收藏 取消收藏

Conoidin A  ≥98%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
立即购买 加入购物车 下载说明书

看了又看
包装规格：100mg in glass bottle
溶解性：溶于DMSO（14.29 mg/mL 超声)
产品描述：基本信息 产品编号：C10790 产品名称：Conoidin A CAS: 18080-67-6   储存条件 粉末 2-8℃ 四年     分子式： C10H8Br2N2O2 溶于液体 -80℃ 两年 分子量 347.99 -20℃ 一个月 化学名：  2,3-BIS(BROMOMETHYL)-1-OXOQUINOXALIN-1-IUM-4(1H)-OLATE   Solubility (25°C)   体外 DMSO 70mg/mL (201.15mM) Ethanol Insoluble Water Insoluble 体内 现配现用   ＜1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。   制备储备液   浓度   溶液体积 质量   1mg   5mg   10mg 1mM 2.8736mL 14.3682mL 28.7365mL 5mM 0.5747mL 2.8736mL 5.7473mL 10mM 0.2874mL 1.4368mL 2.8736mL 50mM 0.0575mL 0.2874mL 0.5747mL   生物活性 产品描述 刚地弓形虫过氧化物酶 II (TgPrxII) 的细胞通透性抑制剂。 靶点/IC50 T.gondii enzyme peroxiredoxin II (TgPrxII） IC50: 23µM   体外研究 Peroxiredoxins are a widely conserved family of enzymes that function in antioxidant defense and signal transduction. And the changes in PrxII expression are associated with a variety of human diseases, including cancer.Conoidin A binds to the peroxidatic cysteine of TgPrxII, inhibiting its enzymatic activity in vitro. Conoidin A also shown toalkylate or crosslink catalytic cysteines of wild type AcePrx-1 in Ancylostoma ceylanicum and human PrxII and PrxIV with similar efficiency. But it is ineffective to mitochondrial hPrxIII.Conoidin A (5µM) can inhibit the glucose oxidase-mediated hyperoxidation of mammalian peroxiredoxin I and II.   体内研究 Conoidin A (intraperitoneal injection; 5mg/kg; for three successive days before MI/R injury) blocks the effect of Luteolin (HYN0162) on the ST‐segment elevation. Furthermore, an increase in the infarct size presented of the MI/R group can be reduced by Luteolin. But pre‐treatment with conoidin A abolishs the effect of Luteolin. Pre‐treatment with conoidin A also prevents Luteolin-reduced activities of CK‐MB, AST and LDH in vivo. Animal Model: Rat myocardial I/R model Dosage: 5mg/kg Administration: Intraperitoneal injection; 5mg/kg; for three successive days before MI/R injury Result: Intraperitoneal injection; 5mg/kg; for three successive days before MI/R injury
保存条件：2-8℃

猜你喜欢